HIGHBuilt-in & outside partyPipeline
AlloNK
“10-K Item 1A: 'We are substantially dependent on the success of our lead product candidate, AlloNK, which is in clinical development.'”
ARTV · Concentration risk · 10-K extracted
Artiva Biotherapeutics (ARTV) concentration risks
Updated
The most significant concentration Artiva Biotherapeutics discloses is AlloNK, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Artiva Biotherapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Artiva Biotherapeutics' concentration risk is entirely pipeline-based: the company is substantially dependent on the success of its lead product candidate, AlloNK, which remains in clinical development. This exposure is disclosed at a high size, and its character is mixed — combining the structural reality of a clinical-stage company built around one lead asset with the dependency risk of needing that asset to clear ongoing development and regulatory hurdles. Because AlloNK is still in clinical development rather than commercialized, the risk here is forward-looking and binary in nature: trial outcomes, regulatory decisions, and continued funding for development will determine whether this concentration resolves favorably, and there is no disclosed secondary program or revenue source to offset a setback. With this as the only disclosed concentration exposure and its size at the high end of the scale, it is effectively the entire investment thesis for the company — there is no diversification across products, customers, or geographies to cushion an adverse clinical or regulatory outcome. This is a name where the concentration risk and the core investment risk are one and the same, appropriate for a clinical-stage biotherapeutics company at this stage of development.
For the engine’s reasoning on ARTV’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ARTV● | Artiva Biotherapeutics, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.